Fujifilm/MediVector antiviral favipiravir advances in Ebola
This article was originally published in Scrip
Executive Summary
Favipiravir (T-705), an antiviral drug that initially was developed by Fujifilm and its US subsidiary MediVector to fight seasonal influenza, is advancing into clinical testing in Guinea as a treatment for Ebola – trials whose preliminary results could be available by as early as year end, a company official said on 11 November.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.